Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: Metastatic breast cancer
How Long am I Going to Live With my Metastatic Breast Cancer?
Metastatic breast cancer (MBC) is a disease that is essentially incurable. Women with MBC are given chemotherapy at some stage of their illness to extend their lives. When starting chemotherapy for MBC, most women would like to know how the … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged estrogen receptor-positive tumors, HER-2, human epidermal growth factor receptor 2-positive, live, Metastatic breast cancer, Survival
|
Comments Off on How Long am I Going to Live With my Metastatic Breast Cancer?
Anorexia and Cachexia – Causes, Symptoms, Diagnosis, Prognosis and Latest Treatment
Anorexia in Cancer Cancer anorexia-cachexia syndrome (CACS) is an extremely common condition in cancer patients. It is estimated that 50% of cancer patients suffered from anorexia. The exact frequency of CACS varies according to the primary pathology (from 30% in … Continue reading →
Posted in Cancer, Gastric Cancer, Others, Pancreatic Cancer
|
Tagged AIDS, Anorexia, Bristol-Myers Squibb, Cachexia, Causes, chemotherapy, cyprohetadine, Diagnosis, dronabinol, Gastric Cancer, Lymphoma, malnutrition, Marinol, Megace, megestrol, Merck, Metastatic breast cancer, orexigenic, Oxandrin, oxandrolone, Pancreatic Cancer, Periactin, Prognosis, Symptoms, Treatment, Unimed, wasting
|
2 Comments
FDA Approves Halaven for Late-Stage Breast Cancer
Good news for patients with late stage metastatic breast cancer. The US Food and Drug Administration (FDA) approved eribulin mesylate injection (Halaven; Eisai, Inc) for the treatment of metastatic breast cancer in patients who have received at least 2 prior … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged anthracycline, Bristol-Myers Squibb, capecitabine, chemotherapy, Eisai, eribulin, Halaven, ixabepilone, Ixempra, Metastatic breast cancer, paclitaxel, resistant, Roche, Survival, taxane, Xeloda
|
Comments Off on FDA Approves Halaven for Late-Stage Breast Cancer
HER2-positive Breast Cancer with Brain Metastases? Use Lapitinibi (Tykerb) and Capecitibine (Xeloda) but NOT Trastuzumab (Herceptin)
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is a disease that accounts for up to one third of all invasive breast tumors. The natural history of this disease, however, has been dramatically improved with the introduction of … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged Brain metastases, Breast cancer, Capecitibine, Her2, Herceptin, Lapitinib, Metastatic breast cancer, Survival, Trastuzumab, Tykerb, Xeloda
|
Comments Off on HER2-positive Breast Cancer with Brain Metastases? Use Lapitinibi (Tykerb) and Capecitibine (Xeloda) but NOT Trastuzumab (Herceptin)
New Hope for Heavily Pretreated Metastatic Breast Cancer Patients
A new chemotherapy agent, eribulin (developed by Eisai), was shown to improve significant survival benefit in heavily pretreated breast cancer, according to the EMBRACE study presented at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The new drug … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged anthracyclines, capecitabine, EMBRACE, eribulin, gemcitabine, halichondrins, Metastatic breast cancer, Survival, taxane, vinorelbine
|
Comments Off on New Hope for Heavily Pretreated Metastatic Breast Cancer Patients
